GSK’s Revolade receives NICE approval for blood disorder treatment
Dubbed as eltrombopag, Revolade is indicated to increase platelet counts in splenectomized patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) and who are refractory to first-line treatments such
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.